Scripta

There are still a dearth of options for treating neurological disease.

Scripta is employing transcription factor (TF) targeting to develop treatments for neuro-focused disease. Founded in 2024, Scripta uses a genome-wide agnostic approach to identify and thereafter modulate TF, which can reset disease signatures at the cellular level. By building sophisticated computational models and leveraging gene regulatory networks, Scripta aims to discover novel drugs capable of treating neurological disease.